Kornimate/medical-research-clean huggingface dataset:
respiratory functions and respiratory muscle strength in patients with temporomandibular joint dysfunction

Conditions: Temporomandibular Joint Dysfunction Syndrome

Summary: in our study, it was aimed to evaluate respiratory functions and respiratory muscle strength in patients diagnosed with temporomandibular dysfunction (tmd) and to compare them with healthy individuals. the study was conducted with a total of 46 participants, 23 of whom were diagnosed with tmd and 23 healthy individuals, at batman training and research hospital between august 2021 and december 2021. in the evaluation, the demographic information and clinical findings of the participants were recorded. mandible movements were evaluated with a digital caliper. for tmj, the visual analogue scale (vas) was used to measure the severity of pain at rest and during activity. cervical lordosis and shoulder posture assessment was done by distance measurement. fonseca anamnestic index was used for tmd severity classification. spirometric measurement was performed to evaluate respiratory functions of all participants and intraoral pressure measurement was performed to determine respiratory muscle strength. statistical analyzes were performed using the ibm spss statistics 26 program. significance level was accepted as p\<0.05.

in our study, it was aimed to evaluate respiratory functions and respiratory muscle strength in patients diagnosed with temporomandibular dysfunction (tmd) and to compare them with healthy individuals. the study was conducted with a total of 46 participants, 23 of whom were diagnosed with tmd and 23 healthy individuals, at batman training and research hospital between august 2021 and december 2021. in the evaluation, the demographic information and clinical findings of the participants were recorded. mandible movements were evaluated with a digital caliper. for tmj, the visual analogue scale (vas) was used to measure the severity of pain at rest and during activity. cervical lordosis and shoulder posture assessment was done by distance measurement. fonseca anamnestic index was used for tmd severity classification. spirometric measurement was performed to evaluate respiratory functions of all participants and intraoral pressure measurement was performed to determine respiratory muscle strength. statistical analyzes were performed using the ibm spss statistics 26 program. significance level was accepted as p\<0.05.

Eligibility criteria:
inclusion criteria: * volunteer to participate in the study. * to be diagnosed with tmd for the tmd group, * to be healthy according to who definition for healthy matched group * being between the ages of 17-50. exclusion criteria: * having any previous pulmonary disease. * to have experienced a tmd problem due to trauma. * having covid-19 in the last 6 months.

Keywords: temporomandibular joint dysfunction syndrome
general anesthesia on blood pressure and intraocular pressure in geriatric patients undergoing cataract surgery

Conditions: Cataract

Summary: the primary aim of the study is to investigate the correlation between preoperative hemodynamics and frailty scores in patients undergoing cataract surgery under general anesthesia. the secondary objective is to explore the relationship between preoperative and postoperative intraocular pressure changes and frailty scores.

cataract stands as a significant cause of vision impairment worldwide, notably prevalent among the elderly. this study aims to explore the changes in intraocular pressure (iop) and blood pressure under general anesthesia during cataract surgery in frail geriatric patients. the research emphasizes the critical role of frailty assessment in determining surgical risks among elderly surgical patients. it focuses on the hypothesis that frail individuals undergoing cataract surgery under general anesthesia might experience more pronounced effects on iop and blood pressure during the surgical procedure compared to prefrail counterparts. this study emerges as a crucial step in understanding the impact of preoperative frailty assessment on surgical planning and outcomes.

Eligibility criteria:
inclusion criteria: * 65-85 age * asa i-iii * cataract surgery with genel anesthesia exclusion criteria: * cerebrovascular disease, * mental retardation and psychiatric illness, * pulmonary infection, history of advanced copd or respiratory failure, * ef less than 40%, presence of cardiovascular disease, * bleeding diathesis, * renal and hepatic insufficiency, * presence of diabetes mellitus, diuretic/mannitol users, * substance abuse * bmi \>30

Keywords: cataract surgery frailty
a study to assess the bioequivalence of different formulations of risedronate in healthy male and female subjects

Conditions: Osteoporosis

Summary: randomized, double-blind, 2-treatment, 2-period, 2-sequence, crossover study, the study will consist of a screening visit, study center admission (preceding treatment periods 1 and 2), 2 treatment periods (4 days each), 1 washout period (14 to 17 days separating periods 1 and 2), and exit procedures.


Eligibility criteria:
inclusion criteria: * male or female, 18 to 65 years of age * if female, non-lactating and either surgically sterile or postmenopausal * body mass index less than or equal to 32 kg/m2 at screening exclusion criteria: * no use of a bisphosphonate within 1 month * no history of gi disease * no use of any medications within 7-14 days prior to scheduled dosing day
randomized clincal trial on the effect of a restricted gluten contamination elimination diet among celiacs [gluced]

Conditions: Celiac Disease

Summary: the study assessed whether compete healing of duodenal mucosa in celiac patients with persistent marsh i-ii lesion after 1 year of gluten free diet (gfd): * could be achieved by adoption of a diet based exclusively on naturally gluten free products, with the elimination of commercially available processed food (gced, gluten contamination elimination diet); * may depend upon time of exposure to gfd. investigators studied two cohorts of celiac patients, both on gfd, for at least one year: * cohort a: patients re-biopsied after three months on gced; * cohort b: patients re-biopsied after a minimum of further two years on standard gfd.

despite strict adherence to gluten free diet (gfd), the complete healing of the duodenal mucosa of celiac patients is rarely achieved. the cause of the persistence of the inflammation is not yet understood. it is well known that there is a high degree of variability in individual response to gluten with some patients worsening of duodenal histology upon exposure to very small amount of gluten. this observation suggest that contamination with gluten of commercially available processed food and/or small amount of gluten in processed foods labeled "gluten-free" (less than 20 ppm) may prevent complete mucosal healing. this explanation is indirectly supported by a study of hollon et al. (2013) showing that persistence of gastrointestinal symptoms in celiac patients on a gfd is abolished, in 85% of cases, by the adoption of a diet based exclusively on naturally gluten-free products, and on the elimination from the diet of commercially available processed food and products labeled "gluten free " (gluten contamination elimination diet, gced). the main aim of this study was to assess whether the complete healing of duodenal mucosa in patients with persistent mars i-ii lesions after 1 year on gfd i) could be achieved, as a proof of the concept, by the adoption of a gced or ii) may depend upon time of exposure to gfd. to achieve this aim investigators studied 2 cohorts of patients with marsh i-ii lesion after 1 year on gfd: cohort a re-byopsied after 3 month gced , and cohort b re-biopsied after a minimum of further 2 years on standard gfd.

Eligibility criteria:
inclusion criteria: * marsh i-ii lesion at 12-18 months after starting gfd * negative celiac disease serology * strict adherence to gluten free diet without digression exclusion criteria: * presence of gastrointestinal symtoms * presence of helicobacter pylori infection

Keywords: celiac disease, gluten free diet gluten contamination
disease characteristics and treatment response in plasma cell disorders patients based on genetic abnormalities from fluorescence in situ hybridization and next generation sequencing

Conditions: Plasma Cell Disorder

Summary: the goal of this observational study is to study the genetic landscape in patients with plasma cell disorders including mgus, smm, mm, and amyloidosis in thailand. the main questions it aims to answer are: * genetic landscape in patients with plasma cell disorders including mgus, smm, mm, and amyloidosis in thailand who were performed fish and/or ngs testing * genetic correlation and genetic dependency between fish and ngs, stratified by high- and standard-risk groups based on fish testing in thai mm patients. * disease characteristics and response rates in mm patients with cytogenetic abnormalities detected by fish and/or genetic mutations detected by ngs. * correlation between cytogenetic abnormalities identified by fish and genetic mutations detected by ngs with progression-free survival in mm patients. the fish and/or ngs testing results, disease characteristics, treatment, and treatment outcomes of patients with plasma cell disorders who underwent fish and/or ngs testing before irb approval will be collected through retrospective chart review. subsequently, data will be gathered prospectively. participants will provide approximately 12 ml of bone marrow fluid for fish and ngs testing.


Eligibility criteria:
inclusion criteria: * patients with plasma cell disorders including mgus, smm, mm, and amyloidosis * aged 18 years and older * performed fish and/or ngs testing * has treatment follow up at least one year exclusion criteria: * patients with missing crucial data that renders them unanalyzable * patients who refuse to participate in the study

Keywords: plasma cell disorder genetic abnormalities fluorescence in situ hybridization fish next generation sequencing ngs
study to compare adhesiveness of two different rotigotine patch formulations

Conditions: Parkinson's Disease

Summary: the primary objective of the study is to compare the adhesiveness of two different patch formulations of rotigotine using patch size 40 cm2, under the assumption that both patch formulations show similar adhesiveness properties.


Eligibility criteria:
inclusion criteria: * subjects with a diagnosis of idiopathic parkinson´s disease, and continuous treatment with commercially available rotigotine transdermal patch for at least 3 months, and a stable rotigotine dose including an 8 mg/24 h patch for at least 2 weeks prior to enrollment exclusion criteria: * subjects has previously participated in this study, failed to be screened, or has participated in another study with an investigational medicinal product (imp) or medical device within the last 30 days or is currently participating in such * subject with a history of significant skin hypersensitivity to adhesives, other transdermal products or recently unsolved contact dermatitis

Keywords: rotigotine neupro
trial of erlotinib, gemcitabine and cisplatin in metastatic pancreatic cancer

Conditions: Metastatic Pancreatic Cancer

Summary: the purpose of this study is to determine the response rate of gemcitabine, cisplatin and erlotinib in metastatic pancreatic cancer.


Eligibility criteria:
inclusion criteria: * age older than 18 * younger than 75 * ecog performance status 0 or 1 * histologically confirmed adenocarcinoma of the pancreas * metastatic pancreatic cancer * no prior chemotherapy for metastatic pancreatic cancer * a patient with at least one measurable primary lesion of which the diameter is confirmed to be 10mm in spiral ct or multidetector ct (md ct) exclusion criteria: * a patient with no measurable disease * a patient who received previous palliative chemotherapy for pancreatic cancer * a patient with locally advanced pancreatic cancer * a patient who received adjuvant chemotherapy for pancreatic cancer within 1 year * a patient with previous active or passive immunotherapy * a pregnant or lactating patient

Keywords: gemcitabine cisplatin erlotinib
noninvasive hemoglobin monitoring by spectrophotometry in blunt abdominal trauma patients for conservative management

Conditions: Intensive Care Unit

Summary: we aimed to study the efficacy of noninvasive hemoglobin monitoring by spectrophotometry in monitoring hemoglobin level in trauma patients for conservative management.


Eligibility criteria:
inclusion criteria: * american society of anesthesiologists (asa) physical status i to iii, of either sex, 18 -80 years of age, non-sedated non-intubated patients who will be admitted to ain shams university hospital - surgical intensive care unit, after blunt abdominal trauma planned for conservation. exclusion criteria: * patients with fever, hypothermia, history of a neurological, psychiatric, dementia or, who are taking psychotropic drugs patients with unstable hemodynamic status, and unconscious patients.

Keywords: massimo
robot-assisted neurovascular intervention

Conditions: Stroke; Meningioma; Neurovascular Disorder

Summary: patients scheduled for neurovascular interventions may be eligible to have their procedure done robotically.

patients scheduled for manual neurovascular interventions, such as diagnostic cerebral angiography for cerebrovascular diseases, arterial embolization for meningioma treatment, and thrombectomy for thrombotic arterial occlusion-induced cerebral ischemia, may be considered to participate in this study.

Eligibility criteria:
inclusion criteria: patients scheduled for neurovascular interventions, such as diagnostic cerebral angiography for cerebrovascular diseases, arterial embolization for meningioma treatment, and thrombectomy for thrombotic arterial occlusion-induced cerebral ischemia, are selected according to the same criteria as standard cerebral angiography and interventional procedures. exclusion criteria: exclusion criteria 1 (general): 1. patients who have undergone surgery within 4 weeks prior to study participation or have not fully recovered from surgery. 2. patients who are pregnant or breastfeeding. 3. patients with existing or anticipated vasospasm, bleeding, or severe atheromatous disease. 4. patients allergic to contrast agents used in angiography. 5. patients with renal failure. 6. patients with a history of cardiac events, such as myocardial infarction or superior vena cava (svc) syndrome, within 3 months prior to study participation, or with existing heart disease. 7. patients unable to cooperate due to difficulty in expressing intent to the extent that the procedure cannot proceed. 8. patients with severe or life-threatening comorbidities that could significantly affect symptom improvement or render the procedure unbeneficial. 9. patients with non-life-threatening comorbidities that prevent proper follow-up for treatment. exclusion criteria 2 (cerebral ischemic stroke patient): 1. patients with an aspects score of 0-2 on a pre-treatment non-contrast ct. 2. inability to perform femoral puncture within 60 minutes of completing ct angiography (if ct perfusion is performed, it must be done after ct angiography). 3. absence of a femoral pulse. 4. cases where vascular access is highly challenging, with an anticipated time exceeding 90 minutes from ct angiography to reperfusion. 5. patients suspected to have cerebral artery dissection or atherosclerosis as the cause of stroke. 6. patients where the intracranial occlusion is determined to be chronic based on clinical history, prior imaging, or clinical judgment.

Keywords: robot-assisted neurovascular intervention cerebral angiogram meningioma thrombectomy ischemic stroke
comparison of the efficiency of two different methods in managing early postoperative thirst

Conditions: Patient Satisfaction; Nursing Caries; Post-Op Complication

Summary: postoperative thirst is one of the most common problems in patients. thirst is a subjective symptom. thirst can cause unwanted problems in patients such as anxiety, discomfort and nausea. it may even cause anxiety, hypertension, dysrhythmia, non-compliance with treatment and increased need for anesthesia. although different methods have been applied in the management of thirst in the existing literature and positive results have been obtained, studies with high evidence value are very limited. the aim of this study was to compare the effectiveness of two different methods in thirst management.

in this study, the investigators compared the effectiveness of two of the methods proposed in the literature for the relief of postoperative thirst. these methods are ice application and wet gauze. a numerical comparison scale was used to assess and monitor thirst (0=no thirst, 10=worst perceived thirst). in patients with a thirst score of 4 and above in the early postoperative period, the duration of thirst severity and the method of quenching thirst with oral ice or wet gauze impregnation were compared. in addition, a control group without any intervention was included. the thirst conditions of these three groups were compared. a total of 240 patients, 80 in each group, were included in the study. oral ice was applied in one group, wet gauze in the second group and no intervention was applied in the third group.

Eligibility criteria:
inclusion criteria: * patients aged 18-65 years * undergoing elective surgery * patients undergoing surgery other than gastrointestinal system surgery * patients in class i, ii, iii according to the american anesthesiologists' association classification (asa) * patients who have completed a minimum of 6 hours of strict fasting and 3 hours of thirst * patients who can verbally express a thirst level of 4 points or more according to visual benchmark scale in the early postoperative period * patients who comply with the safety protocol in the early postoperative period * patients who can express their thirst in the early postoperative period/recovery unit * patients with a duration of surgical anesthesia ≥1 hour and taken to the recovery unit at the end of surgery will be included in the study. exclusion criteria: * emergency planned surgeries * patients who had a second surgical intervention during the hospitalization period * patients who need intensive care after surgery * patients with problems in the extubation process after surgery * patients with altered state of consciousness after surgery * patients with fluid electrolyte imbalance (hypovolemia and sodium imbalance) * patients with swallowing difficulties and fluid intake restriction * foreign patients with language barriers * patients with menthol allergy * patients with problems in the head, neck, throat and mouth will be excluded from the sample. * women who have just given birth and are breastfeeding.

Keywords: thirst management postoperative care surgical patient surgical thirsty
chronic effects of dbs in parkinson's disease and dystonia

Conditions: Parkinson's Disease; Isolated Dystonia

Summary: the purpose of this study is to use an investigational device to record brain activity for 12-24 months following surgical implantation of deep brain stimulation (dbs) systems. the goal of the study is better understanding of brain activity in movement disorders and how they relate to dbs, not to bring new devices to market.


Eligibility criteria:
inclusion criteria(both groups): * ability to give informed consent for the study * movement disorder symptoms that are sufficiently severe, in spite of best medical therapy, to warrant surgical implantation of deep brain stimulators according to standard clinical criteria inclusion criteria (isolated dystonia): * age 22-75 * isolated dystonia that is generalized or segmental, that must affect one or - stable doses of anti-dystonia medications (such as artane, baclofen, or clonopin) for at least 30 days prior to baseline assessment * for patients with craniofacial involvement, prior treatment with botulinum toxin with failure to adequately control dystonia symptoms. inclusion criteria (pd): * age 30-75 * bilateral disease (hoehn and yahr stage 2 or greater) * has been treated with levodopa/carbidopa, and with a dopamine agonist, at the maximal tolerated doses as determined by a movement disorders neurologist * stable doses of antiparkinsonian medications for at least 30 days prior to their baseline assessment * significant disability in the setting of optimal medical management by a movement disorders neurologist. disability may be due to tremor that is unresponsive to medications, or to motor fluctuations * updrs-iii score off medication between 20 and 60 * improvement of at least 30% in the baseline updrs-iii on medication score, compared to the baseline off-medication score. exclusion criteria (both groups): * pregnancy or breast feeding * mri showing cortical atrophy out of proportion to age * mri showing focal brain lesions that could indicate a non-idiopathic movement disorder, * major comorbidity increasing the risk of surgery (prior stroke, severe hypertension, severe diabetes, or need for chronic anticoagulation other than aspirin) * inability to comply with study follow-up visits * any prior intracranial surgery * mood depression with a beck depression inventory score of \> 17 on baseline screening * significant cognitive impairment (moca\<25). * history of seizures * immunocompromised * has an active infection * requires diathermy, electroconvulsive therapy (ect) or transcranial magnetic - has an implanted electronic device such as a neurostimulator, cardiac pacemaker or medication pump.

Keywords: deep brain stimulation cortical recording neuroprosthesis
comparing tapering low dose dexamethasone to other standard of care therapies for taps in breast cancer patients

Conditions: Early-stage Breast Cancer; Pain Syndrome

Summary: the react taps clinical trial will compare a tapering dose of dexamethasone to other standards of care on the presence of taxane-associated pain syndrome (taps) in early stage breast cancer.

taxanes such as docetaxel and paclitaxel are widely used chemotherapeutic agents in patients with early stage breast cancer and is commonly associated with taxane-associated pain syndrome (taps). taps is characterized by disabling pain which usually starts a few days after taxane administration and lasting 2-5 days, often returning following subsequent chemotherapy treatments. taps can significantly reduce a patients quality of life, lead to requirements for potent analgesics, as well as dose reductions/delays or discontinuation of chemotherapy. there is currently no clinical guidelines for the optimal standard of care for the management and prevention of taps. this react clinical trial investigates the optimal management of taps with a tapering dose of dexamethasone (standard premedication comprising 8mg twice daily for 3 days followed by 4mg once a day for 2 days followed by 2mg once a day for 2 days) compared to other standard of care management (i.e. standard premedication with 8mg dexamethasone twice daily for 3 days) as directed by the treating physician. this study will use an "integrated consent model" that involves "oral consent" rather than a written informed consent writing process.

Eligibility criteria:
inclusion criteria: * patients receiving docetaxel-based chemotherapy (docetaxel 75mg/m2 and cyclophosphamide once every 21 days; or docetaxel 75mg/m2 and carboplatin and trastuzumab once every 21 days or fluoro-uracil, epirubicin and cyclophosphamide for 3 cycles once every 21 days, then docetaxel 100mg/m2 once every 21 days; or adriamycin and cyclophosphamide for 3 cycles, then docetaxel 100mg/m2 once every 21 days) for early stage breast cancer. * english literacy and ability to complete questionnaire * ≥19 years of age exclusion criteria: * contraindication to dexamethasone * unable to give informed consent * prior receipt of taxane-based chemotherapy * patient has a significant emotional or psychiatric disorder that in the opinion of the investigator precludes study entry.